Suppr超能文献

母体苯丙酮尿症协作研究(MPKUCS)后代:面部异常、畸形及早期神经后遗症。

Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae.

作者信息

Rouse B, Azen C, Koch R, Matalon R, Hanley W, de la Cruz F, Trefz F, Friedman E, Shifrin H

机构信息

Children's Hospital, University of Texas Medical Branch, Galveston 77555-0319, USA.

出版信息

Am J Med Genet. 1997 Mar 3;69(1):89-95. doi: 10.1002/(sici)1096-8628(19970303)69:1<89::aid-ajmg17>3.0.co;2-k.

Abstract

Maternal phenylketonuria (PKU) in untreated women has resulted in offspring with microcephaly, mental retardation, congenital heart disease (CHD), and intrauterine growth retardation. The Maternal Phenylketonuria Collaborative Study (MPKUCS) was designed to determine the effect of dietary control of blood phenylalanine (Phe) during pregnancy in preventing damage to the fetus associated with untreated Maternal PKU. A cohort of offspring from MPKUS pregnancies was ascertained and examined to evaluate malformations, including CHD, craniofacial abnormalities, microcephaly, intrauterine and postnatal growth retardation, other major and minor defects, and early abnormal neurological signs. For analysis, the women were grouped according to their mean Phe levels in mumol/liter, < or = 360, 361-600, 601-900, or > 900, during critical gestational weeks of 0-8 (N = 203) and 8-12 (N = 190), and average for Phe exposure throughout pregnancy (N = 183). Frequencies of congenital abnormalities increased with increasing maternal Phe levels. Significant relationships included average Phe 0-8 weeks and CHD (P = 0.001); average Phe 8-12 weeks and brain, fetal, and postnatal growth retardation (P < 0.0005 for all), wide nasal bridge (P < 0.0005), and anteverted nares (P = 0.001); and average Phe exposure during the entire pregnancy and neurological signs (P < 0.0005). Although 14% of infants had CHD, none of the CHD occurred at 120-360 mumol/liter and only one (3%) at 361-600 mumol/liter. At levels of 120-360 mumol/liter, there were three infants (6%) with microcephaly, two (4%) with postnatal growth, and none with intrauterine growth retardation, in contrast to 85%, 51%, and 26%, respectively, with Phe above 900 mumol/liter. These data support the concept that women with PKU should begin a low-phenylalanine diet to achieve Phe levels of < 360 mumol/liter prior to conception and should maintain this throughout pregnancy.

摘要

未接受治疗的患有苯丙酮尿症(PKU)的孕妇所生的后代出现了小头畸形、智力发育迟缓、先天性心脏病(CHD)和宫内生长迟缓等情况。苯丙酮尿症孕妇协作研究(MPKUCS)旨在确定孕期控制血液中苯丙氨酸(Phe)水平对预防未治疗的苯丙酮尿症孕妇所生胎儿受损的效果。确定并检查了一组来自MPKUS研究中怀孕妇女的后代,以评估畸形情况,包括先天性心脏病、颅面畸形、小头畸形、宫内和出生后生长迟缓、其他主要和次要缺陷以及早期异常神经体征。为了进行分析,根据孕妇在关键孕周0 - 8周(N = 203)和8 - 12周(N = 190)以及整个孕期苯丙氨酸暴露的平均值(N = 183),以每升微摩尔数为单位,将孕妇分为<或= 360、361 - 600、601 - 900或> 900组。先天性异常的发生率随着孕妇苯丙氨酸水平的升高而增加。显著的相关性包括0 - 8周苯丙氨酸平均值与先天性心脏病(P = 0.001);8 - 12周苯丙氨酸平均值与脑、胎儿及出生后生长迟缓(所有P < 0.0005)、宽鼻梁(P < 0.0005)和鼻孔前倾(P = 0.001);以及整个孕期苯丙氨酸暴露平均值与神经体征(P < 0.0005)。虽然14%的婴儿患有先天性心脏病,但在苯丙氨酸水平为120 - 360微摩尔/升时没有先天性心脏病发生,在361 - 600微摩尔/升时仅有1例(3%)。在苯丙氨酸水平为120 - 360微摩尔/升时,有3例婴儿(6%)患有小头畸形,2例(4%)出生后生长迟缓,没有宫内生长迟缓的情况,相比之下,苯丙氨酸水平高于900微摩尔/升时,小头畸形、出生后生长迟缓和宫内生长迟缓的比例分别为85%、51%和26%。这些数据支持了这样一个观点,即患有苯丙酮尿症的女性在受孕前应开始低苯丙氨酸饮食,以使苯丙氨酸水平达到< 360微摩尔/升,并应在整个孕期维持这一水平。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验